Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market - Yahoo Finance

NVIDIA's recent investment in Generate Biomedicines through its venture arm NVentures has drawn market attention. The biotech company leverages AI to digitally test potential drug molecules for treati... Read original →

NVIDIA’s NVentures stake in Generate Biomedicines isn’t just venture capital—it’s a strategic extension of its GPU compute stack into the foundational layer of drug discovery. This move pressures EDA and genomic sequencing vendors to embed AI inference capabilities, accelerating the displacement of traditional CROs. Regulatory uncertainty looms: if the FDA imposes stringent validation protocols for AI-designed molecules, cash-burn biotechs like Generate face steep compliance overhead. Rivals AMD and Intel will likely counter by deepening ties with AI drug firms like Recursion or Insilico, possibly embedding their IP directly into chip architectures. Within 18 months, if AI platforms demonstrate clinical efficacy in Phase II trials, semiconductor players could shift from selling raw compute to taking revenue shares on drug outcomes—rewiring a $100B+ R&D outsourcing ecosystem.